HANDOK Inc. (002390.KS)
KRW 12270.0
(-2.54%)
KRW 12270.0
(-2.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 522.74 Billion KRW | -3.87% |
| 2022 | 543.75 Billion KRW | 5.05% |
| 2021 | 517.64 Billion KRW | 2.79% |
| 2020 | 503.61 Billion KRW | 6.47% |
| 2019 | 473 Billion KRW | 5.88% |
| 2018 | 446.73 Billion KRW | 6.88% |
| 2017 | 417.97 Billion KRW | 5.51% |
| 2016 | 396.13 Billion KRW | 10.51% |
| 2015 | 358.44 Billion KRW | 2.91% |
| 2014 | 348.31 Billion KRW | 6.21% |
| 2013 | 327.93 Billion KRW | 4.22% |
| 2012 | 314.64 Billion KRW | -5.56% |
| 2011 | 333.17 Billion KRW | 3.78% |
| 2010 | 321.03 Billion KRW | 9.4% |
| 2009 | 293.44 Billion KRW | 6.67% |
| 2008 | 275.09 Billion KRW | 4.6% |
| 2007 | 262.99 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 128.36 Billion KRW | 0.62% |
| 2024 Q1 | 128.77 Billion KRW | 1.73% |
| 2024 Q2 | 128.25 Billion KRW | -0.41% |
| 2023 Q2 | 140.55 Billion KRW | 9.49% |
| 2023 Q1 | 128.37 Billion KRW | -5.62% |
| 2023 FY | 522.74 Billion KRW | -3.87% |
| 2023 Q3 | 127.22 Billion KRW | -9.48% |
| 2023 Q4 | 126.58 Billion KRW | -0.51% |
| 2022 Q3 | 148.57 Billion KRW | 12.49% |
| 2022 Q2 | 132.08 Billion KRW | 3.93% |
| 2022 FY | 543.75 Billion KRW | 5.05% |
| 2022 Q4 | 136.02 Billion KRW | -8.45% |
| 2022 Q1 | 127.08 Billion KRW | -9.1% |
| 2021 Q3 | 134.94 Billion KRW | 8.96% |
| 2021 Q1 | 119.04 Billion KRW | -9.71% |
| 2021 Q2 | 123.84 Billion KRW | 4.03% |
| 2021 Q4 | 139.8 Billion KRW | 3.6% |
| 2021 FY | 517.64 Billion KRW | 2.79% |
| 2020 FY | 503.61 Billion KRW | 6.47% |
| 2020 Q1 | 115.87 Billion KRW | -10.09% |
| 2020 Q2 | 122.68 Billion KRW | 5.87% |
| 2020 Q4 | 131.84 Billion KRW | -1.02% |
| 2020 Q3 | 133.2 Billion KRW | 8.58% |
| 2019 Q1 | 110.79 Billion KRW | -5.04% |
| 2019 Q3 | 119.16 Billion KRW | 4.38% |
| 2019 Q4 | 128.87 Billion KRW | 8.15% |
| 2019 FY | 473 Billion KRW | 5.88% |
| 2019 Q2 | 114.16 Billion KRW | 3.04% |
| 2018 Q2 | 110.3 Billion KRW | 6.26% |
| 2018 Q4 | 116.67 Billion KRW | 0.64% |
| 2018 FY | 446.73 Billion KRW | 6.88% |
| 2018 Q1 | 103.8 Billion KRW | 11.5% |
| 2018 Q3 | 115.93 Billion KRW | 5.1% |
| 2017 Q4 | 93.1 Billion KRW | -17.88% |
| 2017 FY | 417.97 Billion KRW | 5.51% |
| 2017 Q3 | 113.36 Billion KRW | 6.52% |
| 2017 Q2 | 106.43 Billion KRW | 1.3% |
| 2017 Q1 | 105.06 Billion KRW | 2.14% |
| 2016 Q4 | 102.86 Billion KRW | 2.44% |
| 2016 Q1 | 91.22 Billion KRW | -8.38% |
| 2016 FY | 396.13 Billion KRW | 10.51% |
| 2016 Q2 | 101.63 Billion KRW | 11.41% |
| 2016 Q3 | 100.41 Billion KRW | -1.2% |
| 2015 Q3 | 91.44 Billion KRW | 9.73% |
| 2015 Q1 | 84.08 Billion KRW | 0.0% |
| 2015 FY | 358.44 Billion KRW | 2.91% |
| 2015 Q2 | 83.34 Billion KRW | -0.88% |
| 2015 Q4 | 99.57 Billion KRW | 8.88% |
| 2014 FY | 348.31 Billion KRW | 6.21% |
| 2014 Q3 | 89.44 Billion KRW | -2.75% |
| 2014 Q2 | 91.97 Billion KRW | 15.8% |
| 2014 Q4 | - KRW | -100.0% |
| 2014 Q1 | 79.42 Billion KRW | -9.06% |
| 2013 Q1 | 78.91 Billion KRW | 8.38% |
| 2013 FY | 327.93 Billion KRW | 4.22% |
| 2013 Q2 | 79.08 Billion KRW | 0.21% |
| 2013 Q3 | 82.59 Billion KRW | 4.44% |
| 2013 Q4 | 87.33 Billion KRW | 5.74% |
| 2012 Q4 | 72.81 Billion KRW | -11.51% |
| 2012 Q1 | 77.06 Billion KRW | 0.0% |
| 2012 Q2 | 82.48 Billion KRW | 7.04% |
| 2012 Q3 | 82.28 Billion KRW | -0.24% |
| 2012 FY | 314.64 Billion KRW | -5.56% |
| 2011 FY | 333.17 Billion KRW | 3.78% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q3 | 91.62 Billion KRW | 12.88% |
| 2011 Q2 | 81.16 Billion KRW | 4.97% |
| 2011 Q1 | 77.32 Billion KRW | -10.01% |
| 2010 Q1 | 70.95 Billion KRW | -9.13% |
| 2010 FY | 321.03 Billion KRW | 9.4% |
| 2010 Q2 | 80.36 Billion KRW | 13.27% |
| 2010 Q3 | 83.79 Billion KRW | 4.28% |
| 2010 Q4 | 85.92 Billion KRW | 2.54% |
| 2009 Q1 | 71.53 Billion KRW | 1.7% |
| 2009 Q3 | 72.81 Billion KRW | 2.53% |
| 2009 Q2 | 71.01 Billion KRW | -0.73% |
| 2009 Q4 | 78.08 Billion KRW | 7.24% |
| 2009 FY | 293.44 Billion KRW | 6.67% |
| 2008 Q2 | 70.78 Billion KRW | 7.03% |
| 2008 Q3 | 67.84 Billion KRW | -4.16% |
| 2008 Q4 | 70.33 Billion KRW | 3.68% |
| 2008 FY | 275.09 Billion KRW | 4.6% |
| 2008 Q1 | 66.13 Billion KRW | -4.47% |
| 2007 Q4 | 69.22 Billion KRW | 15.92% |
| 2007 Q3 | 59.72 Billion KRW | -14.59% |
| 2007 Q2 | 69.92 Billion KRW | 9.06% |
| 2007 Q1 | 64.11 Billion KRW | 0.0% |
| 2007 FY | 262.99 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -280.98% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 53.822% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 18.123% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -286.15% |
| Yuhan Corporation | 1858.98 Billion KRW | 71.88% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 21.272% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -906.141% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 64.938% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -287.474% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -41.076% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -490.044% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | -208.279% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | -132.892% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -280.98% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -569.724% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | -246.023% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -498.351% |
| JW Holdings Corporation | 928.07 Billion KRW | 43.674% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 12.986% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 68.687% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 30.164% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -161.072% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | -189.186% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | -166.235% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 28.036% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -280.98% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 65.483% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 61.992% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 30.164% |
| Yuhan Corporation | 1858.98 Billion KRW | 71.88% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 34.223% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | -122.535% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 12.08% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 30.164% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | -78.942% |
| Korea United Pharm Inc. | 278.94 Billion KRW | -87.4% |
| CKD Bio Corp. | 160.35 Billion KRW | -225.994% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 0.799% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | -44.76% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | -126.89% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | -161.072% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 40.583% |
| Boryung Corporation | 859.62 Billion KRW | 39.19% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -315.11% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | -41.076% |
| JW Lifescience Corporation | 206.86 Billion KRW | -152.702% |